Dr. Angel Veloso Jr., MD

Dr. Veloso practices at Endoscopy Center of Miami in Miami, Florida.

Dr. Veloso's NPI, 1477589505, was assigned on June 23, 2006. Dr. Veloso holds Florida license ME0039123.

Dr. Veloso's primary practice is Endoscopy Center of Miami, at 5101 Sw 8th St, Miami, FL 33134. The practice phone is (305) 461-1881.

Dr. Veloso's primary practice is Endoscopy Center of Miami in Miami, Florida. The medical group on file is GastroMed. Dmand AI also links Dr. Veloso to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Veloso practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Veloso's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Veloso is licensed in Florida.

CMS data shows 194 Medicare services from Dr. Veloso across 3 procedure codes in 2024, all of them office visits, for 129 Medicare patients. Medicare paid $17,510 for them. Every service was in an office.

CMS counts 129 Medicare patients who saw Dr. Veloso in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 68% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Veloso's median patient age at 63, with 60% women.

In 2024, Dr. Veloso wrote 6,110 Medicare Part D claims for 1,465 patients. 89% of them were for generic drugs. CMS names the drug for 5,938 of them, across 44 drugs with 11 or more claims each, at $615,997 in total drug cost. In 2023, CMS named 5,797 claims across 41 drugs.

Dr. Veloso accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1,082 general payments to Dr. Veloso from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $3,094.